Form 4: Celcuity Director Romp Acquires Restricted Stock

Celcuity Inc. Director Charles R. Romp acquired 215 shares of restricted common stock, vesting by April 30, 2026.

Summary

• Charles R. Romp, a Director of Celcuity Inc. (CELC), acquired 215 shares of common stock.
• The transaction occurred on February 11, 2026.
• The acquired shares are restricted stock, which will vest upon the earliest of Celcuity Inc.'s 2026 annual meeting of stockholders or April 30, 2026.
• The transaction price for these shares was $0, indicating a grant rather than a purchase.
• Following this reported transaction, Charles R. Romp beneficially owns 215 shares directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents routine director compensation through an equity grant, aligning the director's interests with long-term shareholder value.

Positives

• The grant of restricted stock to a director aligns their interests with the long-term performance and shareholder value of Celcuity Inc.
• Equity compensation at a $0 price is a standard practice for incentivizing board members.

Future Outlook

The restricted stock grant indicates a future vesting event tied to either the 2026 annual meeting of stockholders or April 30, 2026, whichever occurs first, signaling continued alignment of the director with the company's future performance.

Industry Context

StockSavvy.ai notes that equity grants to directors are a standard practice in the biotechnology and pharmaceutical industry, aiming to align leadership interests with long-term shareholder value. This particular grant to a director of Celcuity Inc. is consistent with typical compensation structures for board members in similar-sized companies.

Comparison to Industry Standards

• The grant of restricted stock at a $0 price is a common method of non-cash compensation for directors across various industries, including biotech, aligning their incentives with company performance.
• The vesting schedule, tied to an annual meeting or a specific date within the next year, is typical for director equity awards, similar to practices seen at companies like Bio-Techne (TECH) or Exact Sciences (EXAS) for their non-employee directors.

Stakeholder Impact

• Shareholders: The grant of restricted stock to a director aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Vesting of the 215 restricted shares upon the earliest of Celcuity Inc.'s 2026 annual meeting of stockholders or April 30, 2026.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a director as part of their compensation package. While it indicates continued insider ownership and alignment, it does not represent a significant market-moving event or a strong signal for a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as it doesn't provide new information to alter existing positions.

Keywords

Celcuity Inc., CELC, Charles R. Romp, Form 4, Insider Transaction, Restricted Stock, Director Compensation, Equity Grant